[UFT/CDDP treatment in advanced gastric cancer--case report]. 1989

S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
Dept. of Gastroenterology, National Nagoya Hospital.

In treating advanced gastric cancer cases, 100 mg/m2 of cisplatin (CDDP) was given to such patients by means of a 24 hr continuous iv infusion once a month. This was in addition to daily UFT chemotherapy with an oral administration of UFT at a dose of 200 mg/m2 twice a day before meals. In this paper, two patients who achieved an objective tumor response to this UFT/CDDP chemotherapy are discussed. It was felt that this treatment was not likely to induce either leukocytopenia or thrombocytopenia. With regard to this drug combination, it has been reported that a remarkable, synergistic, antitumoral activity of combined 5-fluorouracil and cisplatin was demonstrated against L-1210 leukemia in BDF1 mice.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
November 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
June 1987, Gan no rinsho. Japan journal of cancer clinics,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
October 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
January 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
September 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
October 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
December 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
March 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
April 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
S Suga, and H Nagai, and Y Horiuchi, and T Ohkita, and J Ibayashi, and Y Koyama
March 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!